Tell me your next 10X investment and one sentence about the thesis.

I had NVDA as my 7X. Never did 10X.

Imagine a homeless person who moves around frequently. She previously rented a place and used her salary to steadily accumulate gold. Now she has accepted a new job that requires her to travel internationally throughout the year, which makes renting a home impractical.

Because she will be traveling across many countries, she faces strict limits on what she can carry. Some countries allow less than 1 oz of gold, and others prohibit carrying gold altogether. Given these restrictions, she’s unsure what to do with her gold stack.

She is currently considering storing it in a third‑party vault, such as the TDS vault offered by JM Bullion, since she can physically deliver her gold there. Does anyone have experience with this service? Any ideas or suggestions are welcome.

Written by me, refined by Gemini.

UnitedHealth Group (UNH) released their Q1 2026 results recently, and the data suggests a significant shift in operational performance compared to the volatility seen in 2024. Instead of relying on management narratives, let's look at the actual divergence between expectations and results.

The Earnings Snapshot

The 2024 fiscal year was clearly a trough, heavily impacted by the Change Healthcare cyberattack and non-recurring divestitures. Looking at the EPS trajectory helps frame the current recovery.

Fiscal Year	Reported/Projected EPS	Status
2023	$23.86	Actual
2024	$15.51	Actual (Impacted Year)
2026	>$18.25	Guidance (Projected)

The "Beat" and Expectation Shift

The most interesting aspect of the Q1 2026 report isn't just the beat—it’s how the operational metrics (specifically the Medical Care Ratio) influenced the guidance adjustment. The market was expecting a more conservative Q1, and the reality forced an upward revision in the company's full-year outlook.

Metric	Consensus Estimate	Actual Results	Delta / Context
Q1 2026 EPS	$6.59	$7.23	~9.7% Positive Surprise
Q1 2026 Revenue	$109.44B	$111.7B	~2% YoY Growth
FY 2026 Guidance	~$18.00	>$18.25	Upward Revision

Key Takeaway: MCR Discipline

Rather than taking management's word that "things are going well," the metric that actually matters here is the Medical Care Ratio (MCR).

• Q1 2025 MCR: 84.8%
• Q1 2026 MCR: 83.9%

A 90-basis-point improvement in MCR is the primary driver behind the earnings beat. They are successfully managing their medical costs relative to premiums. The "recovery" narrative holds weight only because the margin discipline has returned, not because of top-line revenue expansion or executive promises.

The company is trading at a point where the market is pricing in the stabilization. If the MCR holds below 84% for the remainder of the year, the guidance of >$18.25 looks conservative.

Made 4x on Meta and 2x in GOOGL recently. Evaluating if I should sell, but the question is buy what?

I remember timing NVDA peak in 2021 and selling. It did not end well. I did make 7x on that investment. I wish I had kept it. I sold that to buy BABA but then got burnt around 40%.

Question:

Maybe I should sell a little but then buy what. I did buy little MSFT already. I also have CNSWF and some ADBE. I also have positions in COST AAPL etc, they are old but not too big positions.